# Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT00907218** · PHASE4 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Attention Deficit/Hyperactivity Disorder
- Smoking Cessation

## Interventions

- **DRUG:** Varenicline (Chantix)

## Key facts

- **NCT ID:** NCT00907218
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** extremely slow enrollment
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907218, "Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00907218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*